在创伤患者知情同意试验的例外情况下,对监管批准的时间分析

Shannon W Stephens1, Christy R Carroll-Ledbetter, Sarah Duckert

  • 1From the Department of Surgery (S.W.S., C.R.C.-L., S.D., T.W.C., M.A.N., J.R., J.B.H., J.O.J.), Center for Injury Science, and Department of Epidemiology (R.L.G.), University of Alabama at Birmingham, Birmingham, Alabama; Avania Clinical (S.G.), Marlborough, Massachusetts; CSL Behring (A.S., J.C., S.R.S., B.G., J.R., J.D.), King of Prussia, Pennsylvania; Office of Institutional Review Board (A.J.M.), University of Alabama at Birmingham, Birmingham, Alabama; Advarra (L.G., A.H.), Columbia, Maryland; and Department of Surgery (B.J.), University of Arizona, Tucson, Arizona.

概括

社区咨询对于知情同意试验的例外可能是有效的,但行政障碍会导致严重的延误. 协调本地流程是加速临床试验启动和执行的关键.